Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
The Zacks Analyst Blog Highlights: Apple, Mastercard, Verizon, Target and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Mastercard, Verizon, Target and Gilead Sciences
Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study
by Zacks Equity Research
Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.
Top Research Reports for Apple, Mastercard & Verizon
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Mastercard Incorporated (MA), and Verizon Communications Inc. (VZ).
3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data
by Zacks Equity Research
Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.
Gilead (GILD) Tecartus Gets FDA Nod for Leukemia Indication
by Zacks Equity Research
Following FDA approval, Gilead's (GILD) Tecartus becomes the first and only CAR T-cell therapy approved for treating relapsed/refractory B-cell acute lymphoblastic leukemia in adult patients.
Gilead (GILD) Files sBLA to FDA for Yescarta Label Expansion
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary, Kite, submits an sBLA to the FDA for Yescarta to treat relapsed/refractory large B-cell lymphoma in the second-line setting.
Gilead Sciences (GILD) Stock Moves -0.62%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $69.97, marking a -0.62% move from the previous day.
AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies
by Zacks Equity Research
AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.
Gilead Sciences (GILD) Stock Moves -0.91%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $70.96 in the latest trading session, marking a -0.91% move from the prior day.
Gilead Sciences (GILD) Stock Moves 0.23%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $71.15, marking a +0.23% move from the previous day.
Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study
by Zacks Equity Research
Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $72.34, moving +0.65% from the previous trading session.
Merck (MRK) Begins Molnupiravir Study for COVID Prevention
by Zacks Equity Research
Merck (MRK) starts enrolling participants in phase III study to evaluate its oral investigational antiviral for the prevention of COVID-19.
Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study
by Zacks Equity Research
Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.
Bristol Myers (BMY) CAR T Cell Therapy Abecma Approved by EC
by Zacks Equity Research
Bristol Myers (BMY) wins EC approval for its CAR T cell immunotherapy, Abecma, for the treatment of multiple myeloma.
Gilead (GILD) MAA for HIV Inhibitor Under the EMA's Review
by Zacks Equity Research
Gilead's (GILD) application for an investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, is under review with the European regulatory body.
Delta Variant Catches Up with the Stock Market
by Mark Vickery
Today, worries about growth and demand, at least partially caused by the Delta variant of Covid-19 manifesting in pockets of America.
Allogene's (ALLO) CAR T Therapy Gets Orphan Drug Status
by Zacks Equity Research
Allogene's (ALLO) CAR T therapy, ALLO-715, gets orphan-drug designation in the United States. It is a potential treatment for multiple myeloma and other BCMA-positive malignancies.
How Are Biotech ETFs Reacting to These Q2 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, McDonald's, Union Pacific Corp, Gilead Sciences and Uber
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, McDonald's, Union Pacific Corp, Gilead Sciences and Uber
Top Stock Reports for Thermo Fisher, McDonald's & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), McDonald's Corporation (MCD), and Union Pacific Corporation (UNP).
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the second quarter.
Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.
Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.